Thanks for your analysis @jaluma much appreciated. That bloody...

Thanks for your analysis @jaluma much appreciated. That bloody JV. It really needs to be in profit by now, otherwise why have all the risk exposure and no return? Whilst the BOD keeps on spinning it as a great and valuable asset, this asset is costing Beam a lot of money annually.

Is there any visibility in the report/presentation on the uptake/impact from the European Zoleo rollout?

Haven't watched the presentation though so I'll reserve any other comments until then.

Note: It is really reassuring that the new Beam product is placed outside of the JV structure.